Literature DB >> 33676050

Complications of switching from anti-IL-5 or anti-IL-5R to dupilumab in corticosteroid-dependent severe asthma.

Katrien Eger1, Lodewijk Pet2, Els J M Weersink2, Elisabeth H Bel2.   

Abstract

Entities:  

Year:  2021        PMID： 33676050     DOI： 10.1016/j.jaip.2021.02.042

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


× No keyword cloud information.
  8 in total

1.  Hypereosinophilia management in patients with type 2 chronic rhinosinusitis treated with dupilumab: preliminary results.

Authors:  Alessandro Vinciguerra; Andrea Rampi; Mona-Rita Yacoub; Moreno Tresoldi; Umberto Tanzini; Mario Bussi; Matteo Trimarchi
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-04-21       Impact factor: 3.236

2.  Real-World Effectiveness of Dupilumab for Patients with Severe Asthma: A Retrospective Study.

Authors:  Takanori Numata; Jun Araya; Hanae Miyagawa; Keitaro Okuda; Daisuke Takekoshi; Mitsuo Hashimoto; Shunsuke Minagawa; Takeo Ishikawa; Hiromichi Hara; Kazuyoshi Kuwano
Journal:  J Asthma Allergy       Date:  2022-04-01

3.  Severe Asthma Where Eosinophilic Granulomatosis with Polyangiitis Became Apparent after the Discontinuation of Dupilumab.

Authors:  Miki Ikeda; Nobuharu Ohshima; Masahiro Kawashima; Meiko Shiina; Masashi Kitani; Maho Suzukawa
Journal:  Intern Med       Date:  2021-08-13       Impact factor: 1.271

Review 4.  Biologics in Asthma: A Molecular Perspective to Precision Medicine.

Authors:  Brittany Salter; Paige Lacy; Manali Mukherjee
Journal:  Front Pharmacol       Date:  2022-01-19       Impact factor: 5.810

Review 5.  Specific Therapy for T2 Asthma.

Authors:  Diego Bagnasco; Elisa Testino; Stefania Nicola; Laura Melissari; Maria Russo; Rikki Frank Canevari; Luisa Brussino; Giovanni Passalacqua
Journal:  J Pers Med       Date:  2022-04-07

6.  Exacerbation of Eosinophilic Granulomatosis With Polyangiitis After Administering Dupilumab for Severe Asthma and Eosinophilic Rhinosinusitis With Nasal Polyposis.

Authors:  Shunya Tanaka; Taisuke Tsuji; Shinsuke Shiotsu; Tatsuya Yuba; Noriya Hiraoka
Journal:  Cureus       Date:  2022-05-22

7.  Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis.

Authors:  Cristiano Caruso; Paolo Cameli; Elena Altieri; Maria Aliani; Pietro Bracciale; Luisa Brussino; Maria Filomena Caiaffa; Giorgio Walter Canonica; Stefano Centanni; Maria D'Amato; Stefano Del Giacco; Fausto De Michele; Elide Anna Pastorello; Girolamo Pelaia; Paola Rogliani; Micaela Romagnoli; Pietro Schino; Marco Caminati; Alessandra Vultaggio; Alessandro Zullo; Sara Rizzoli; Silvia Boarino; Gianfranco Vitiello; Francesco Menzella; Fabiano Di Marco
Journal:  Front Med (Lausanne)       Date:  2022-09-02

Review 8.  The Role of T Helper Type 2 (Th2) Cytokines in the Pathogenesis of Eosinophilic Granulomatosis with Polyangiitis (eGPA): an Illustrative Case and Discussion.

Authors:  Megan E Milne; Jack Kimball; Teresa K Tarrant; Rami N Al-Rohil; David L Leverenz
Journal:  Curr Allergy Asthma Rep       Date:  2022-09-14       Impact factor: 4.919
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.